Ceryvyn Therapeutics Limited CYVNY
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -100.00% | -97.58% | -97.64% | -99.06% |
| Total Other Revenue | -- | -- | -- | -- | -110.00% |
| Total Revenue | 100.00% | 100.00% | -99.62% | -99.63% | -112.67% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 100.00% | 100.00% | -99.62% | -99.63% | -112.67% |
| SG&A Expenses | -82.14% | -82.17% | -75.46% | -76.21% | 71.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -90.10% | -90.12% | -- | -- | 145.73% |
| Total Operating Expenses | -95.10% | -95.11% | -94.59% | -94.75% | -27.84% |
| Operating Income | 95.10% | 95.11% | 94.58% | 94.74% | 27.79% |
| Income Before Tax | 79.07% | 79.10% | 262.77% | 257.79% | 73.16% |
| Income Tax Expenses | 79.87% | 79.90% | 100.64% | 100.62% | 78.40% |
| Earnings from Continuing Operations | 79.04% | 79.08% | 270.22% | 265.02% | 72.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 79.04% | 79.08% | 270.22% | 265.02% | 72.97% |
| EBIT | 95.10% | 95.11% | 94.58% | 94.74% | 27.79% |
| EBITDA | 95.11% | 95.12% | 94.58% | 94.75% | 27.78% |
| EPS Basic | 80.77% | 81.25% | 255.58% | 250.99% | 84.99% |
| Normalized Basic EPS | 80.95% | 81.71% | 249.29% | 244.60% | 85.03% |
| EPS Diluted | 80.77% | 81.25% | 255.58% | 250.99% | 84.99% |
| Normalized Diluted EPS | 80.95% | 81.71% | 249.29% | 244.60% | 85.03% |
| Average Basic Shares Outstanding | 11.18% | 11.18% | 9.27% | 9.27% | 79.76% |
| Average Diluted Shares Outstanding | 11.18% | 11.18% | 9.27% | 9.27% | 79.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |